收稿日期: 2023-09-22
网络出版日期: 2024-03-06
基金资助
河南省医学科技攻关计划（联合共建）项目(LHGJ20190511)
Levels and clinical significance of serum miR-651 and miR-630 in patients with cervical cancer
Received date: 2023-09-22
Online published: 2024-03-06
目的 探究宫颈癌患者血清微小RNA（miR）-651和miR-630水平及临床意义。 方法 收集2017年6月至2020年5月入院治疗的宫颈癌患者108例为宫颈癌组，同时选取在我院治疗的宫颈上皮内瘤变（CIN）患者100例为CIN组，以及同期在本院健康体检者110例为对照组。实时荧光定量PCR（qRT-PCR）检测血清miR-651、miR-630水平，分析血清miR-651、miR-630与宫颈癌患者临床特征和预后的关系。 结果 宫颈癌组、CIN组血清miR-651、miR-630水平显著低于对照组（P < 0.05），宫颈癌组血清miR-651、miR-630水平显著低于CIN组（P < 0.05）。血清miR-651与miR-630表达水平呈正相关（r = 0.660，P < 0.05）。血清miR-651、miR-630水平与HPV感染、分化程度、淋巴结转移、FIGO分期有关（P < 0.05）。miR-651和miR-630低水平患者总生存率低于高水平患者。Cox回归分析表明，HPV感染、分化程度、淋巴结转移、FIGO分期、miR-651、miR-630均是宫颈癌患者预后的影响因素（P < 0.05）。 结论 宫颈癌患者血清miR-651、miR-630水平降低，两者与HPV感染、分化程度、淋巴结转移、FIGO分期及预后有关。
张永珍 , 王珊珊 , 赵海灵 , 徐丽伟 . 宫颈癌患者血清miR-651、miR-630水平及临床意义[J]. 实用医学杂志, 2024 , 40(2) : 158 -162 . DOI: 10.3969/j.issn.1006-5725.2024.02.006
Objective To investigate the levels and clinical significance of serum microRNA （miR）-651 and miR-630 in patients with cervical cancer. Methods From June 2017 to May 2020， 108 cervical cancer patients accepted by our hospital were collected as the cervical cancer group. Meantime， 100 cervical intraepithelial neoplasia （CIN） patients treated in our hospital were regarded as the CIN group， and 110 healthy individuals who underwent physical examination were regarded as the control group. Real-time fluorescence quantitative PCR （qRT-PCR） was applied to detect serum levels of miR-651 and miR-630， while analyzing the relationship between serum miR-651 and miR-630 as well as clinical features and prognosis of patients. Results The serum levels of miR-651 and miR-630 in the cervical cancer group and CIN group were obviously lower than those in the control group （P<0.05）， while the serum levels of miR-651 and miR-630 in the cervical cancer group were obviously lower than those in the CIN group （P < 0.05）. The expression levels of serum miR-651 and miR-630 were positively correlated （r = 0.542， P < 0.05）. The serum levels of miR-651 and miR-630 were related to HPV infection， differentiation， lymph node metastasis， and FIGO staging （P < 0.05）. The overall survival rate of patients with low levels of miR-651 and miR-630 was lower than that of patients with high levels. Cox regression analysis showed that， HPV infection， degree of differentiation， lymph node metastasis， FIGO staging， miR-651， and miR-630 were all influencing factors for the prognosis of cervical cancer patients （P < 0.05）. Conclusion The serum levels of miR-651 and miR-630 in cervical cancer patients decrease， which are related to HPV infection， differentiation， lymph node metastasis， FIGO staging， and prognosis.
Key words： cervical cancer; Micro RNA-651; Micro RNA-630
| 1 | REVATHIDEVI S， MURUGAN A K， NAKAOKA H， et al. APOBEC： A molecular driver in cervical cancer pathogenesis［J］. Cancer Lett， 2021， 496（1）：104-116. doi:10.1016/j.canlet.2020.10.004 |
| 2 | 冯同富. 宫颈癌筛查策略的变迁及思考［J］. 实用医学杂志， 2022，38（15）：1865-1871. doi:10.3969/j.issn.1006-5725.2022.15.004 |
| 3 | GENNIGENS C， DE CUYPERE M， HERMESSE J， et al. Optimal treatment in locally advanced cervical cancer［J］. Expert Rev Anticancer Ther， 2021， 21（6）：657-671. doi:10.1080/14737140.2021.1879646 |
| 4 | YUAN Y， CAI X， SHEN F， et al. HPV post-infection microenvironment and cervical cancer［J］. Cancer Lett， 2021， 497（1）：243-254. doi:10.1016/j.canlet.2020.10.034 |
| 5 | GüZEL C， VAN STEN-VAN'T HOFF J， DE KOK IMCM， et al. Molecular markers for cervical cancer screening［J］. Expert Rev Proteomics， 2021， 18（8）：675-691. doi:10.1080/14789450.2021.1980387 |
| 6 | BA?UELOS-VILLEGAS E G， PéREZ-YPéREZ M F， ALVAREZ-SALAS L M. Cervical Cancer， Papillomavirus， and miRNA Dysfunction［J］. Front Mol Biosci， 2021， 8：758337. doi:10.3389/fmolb.2021.758337 |
| 7 | ZHU X， LONG L， XIAO H， et al. Cancer-Derived Exosomal miR-651 as a Diagnostic Marker Restrains Cisplatin Resistance and Directly Targets ATG3 for Cervical Cancer［J］. Dis Markers. 2021， 2021：1544784. doi:10.1155/2021/1544784 |
| 8 | WANG Q， DING J， NAN G， et al. LncRNA NOC2L-4.1 functions as a tumor oncogene in cervical cancer progression by regulating the miR-630/YAP1 pathway［J］. J Cell Biochem， 2019， 120（10）：16913-16920. doi:10.1002/jcb.28949 |
| 9 | BHATLA N， BEREK J S， CUELLO FREDES M， et al. Revised FIGO staging for carcinoma of the cervix uteri［J］. Int J Gynaecol Obstet， 2019， 145（1）：129-135. doi:10.1002/ijgo.12749 |
| 10 | RAJARAM S， GUPTA B. Screening for cervical cancer： Choices & dilemmas［J］. Indian J Med Res， 2021， 154（2）：210-220. |
| 11 | 苏博， 闫振宇， 郝尚辉， 等. 宫颈癌患者癌组织中IL-33表达水平与临床病理特征及预后的相关性［J］. 实用医学杂志， 2021， 37（17）：2214-2218. doi:10.3969/j.issn.1006-5725.2021.17.009 |
| 12 | WANG Y， ZHANG Z， TAO P， et al. The Abnormal Expression of miR-205-5p， miR-195-5p， and VEGF-A in Human Cervical Cancer Is Related to the Treatment of Venous Thromboembolism［J］. Biomed Res Int， 2020， 2020：3929435. doi:10.1155/2020/3929435 |
| 13 | AFTAB M， POOJARY S S， SESHAN V， et al. Urine miRNA signature as a potential non-invasive diagnostic and prognostic biomarker in cervical cancer［J］. Sci Rep， 2021， 11（1）：10323. doi:10.1038/s41598-021-89388-w |
| 14 | OCADIZ-DELGADO R， LIZCANO-MENESES S， TREJO-VAZQUEZ J A， et al. Circulating miR-15b， miR-34a and miR-218 as promising novel early low-invasive biomarkers of cervical carcinogenesis［J］. APMIS， 2021， 129（2）：70-79. doi:10.1111/apm.13093 |
| 15 | ZHAO H， YANG X， LIU J， et al. Overexpression of miR-651-5p inhibits ultraviolet radiation-induced malignant biological behaviors of sebaceous gland carcinoma cells by targeting ZEB2［J］. Ann Transl Med， 2022， 10（9）：517. doi:10.21037/atm-21-3897 |
| 16 | ZOU L， SUN P， ZHANG L. miR-651-3p Enhances the Sensitivity of Hepatocellular Carcinoma to Cisplatin via Targeting ATG3-Mediated Cell Autophagy［J］. J Oncol， 2021， 2021：5391977. doi:10.1155/2021/5391977 |
| 17 | YU S， RUAN X， LIU X， et al. HNRNPD interacts with ZHX2 regulating the vasculogenic mimicry formation of glioma cells via linc00707/miR-651-3p/SP2 axis［J］. Cell Death Dis， 2021， 12（2）：153. doi:10.1038/s41419-021-03432-1 |
| 18 | WANG B， LI J， LI Y， et al. MiR-630 suppresses non-small cell lung cancer by targeting vimentin［J］. J Clin Lab Anal， 2022， 36（9）：e24536. doi:10.1002/jcla.24536 |
| 19 | LIU X， WU W， ZHANG S， et al. Effect of miR-630 expression on esophageal cancer cell invasion and migration［J］. J Clin Lab Anal， 2021， 35（6）：e23815. doi:10.1002/jcla.23815 |
| 20 | GAO Q， REN Z， JIAO S， et al. HIF-3α-Induced miR-630 Expression Promotes Cancer Hallmarks in Cervical Cancer Cells by Forming a Positive Feedback Loop［J］. J Immunol Res， 2022， 2022：5262963. doi:10.1155/2022/5262963 |
/
| 〈 |
|
〉 |